Curator's Take
This breakthrough represents a significant milestone in quantum computing's journey toward practical applications in drug discovery and molecular biology. By simulating a protein complex with over 12,000 atoms—far exceeding previous quantum simulation capabilities—the collaboration demonstrates that current quantum hardware can already tackle biologically relevant problems, even in the noisy intermediate-scale quantum (NISQ) era. The partnership between Cleveland Clinic's medical expertise, RIKEN's computational prowess, and IBM's quantum systems showcases how hybrid classical-quantum approaches are becoming the pragmatic path forward for complex molecular modeling. While we're still years away from quantum advantage in drug discovery, this work proves that quantum computers are evolving from laboratory curiosities into tools that can contribute meaningfully to real-world scientific challenges.
— Mark Eatherly
Summary
Insider Brief PRESS RELEASE — Scientists at Cleveland Clinic, RIKEN, and IBM (NYSE: IBM) have used IBM quantum computers and two of the world’s most powerful supercomputers to simulate protein complexes spanning up to 12,635 atoms. These are the largest-known simulations of biologically meaningful molecules performed with quantum hardware yet, and signal that quantum computers […]